Oligometastatic prostate cancer lacks clear guidelines. GROUQ-PCS 9 shows SBRT + ADT + enzalutamide cuts progression/death by 52%. STOMP and ORIOLE support MDT benefit. Risks of over- vs. under-treatment remain. Learn more from Benjamin Garmezy & @Mkbupathi! mashupmd.com/expert-collect…

April serves as #TesticularCancerAwarenessMonth, which is the most common type of cancer in men aged between 15 and 44 years old. Watch more from Dr. Garmezy (Benjamin Garmezy), of Sarah Cannon Docs, here: curetoday.com/view/early-det…

And shout out to Sarah Cannon Docs for participating in so much data this year being presented at ASCO! SCRI Oncology Partners

For those that cannot attend the annual @asco meeting.... we have created a local meeting w/my co-chair 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 in #heme and #solidtumors. Join us! Muhamed Baljević, MD, FACP Kathy Walsh, MD, MAEd Chris Cann, MD Benjamin Garmezy Christine Lovly, MD, PhD, FASCO Date: Sat 6/21/2025 Location: Conrad Hotel #nashville

Excited for this conference in Nashville. Will be a great opportunity for education and networking in Gu cancers! IDEOlogy Health World GU Conference

#ASCO25 kicks off the conversation. #WorldGU25 delivers focused updates on bladder, prostate, and kidney cancers. With esteemed faculty like Drs. Matt Milowsky, Michael Harrison, Jean Hoffman-Censits, Benjamin Garmezy, Dr. Darren Feldman, and nearly 60 other multidisciplinary thought leaders, this

Happy to present Stellar-002 phase 1b study with zanzalitinib (tki) + nivo or Nivo/rela. Add to the front line RCC data presented by jc. Compelling activity and durability in a pre treated population! #ASCO25 Sarah Cannon Docs lots of hard work and thanks to the patients!

And follow Oncology Decoded for more!

Thanks to manojkumar John Burke and Dhaval shah for allowing me to host remotely! A really unique listen. Dr Burke taught me a lot. Thanks The US Oncology Network for hosting us! Sarah Cannon Docs SCRI Oncology Partners Please listen: links on website, Apple, Spotify and send feedback!

NEW in @OncogeneJournal: MiNK Therapeutics reports complete remission in metastatic, SOC + ICI-refractory testicular cancer with allo-iNKT (agenT-797) ✔️ Durable survival ✔️ No lymphodepletion ✔️ No GVHD 🔗 Builds on 2L gastric PFS + >12mo OS nature nature.com/articles/s4138…

Excited to share a story about the power of clinical trials! Please see our article on oncogene examining a robust and durable response with iNKT cell therapy in a patient with very refractory germ cell tumor. Sarah Cannon Docs and SCRI Oncology Partners nature.com/articles/s4138…

🧠 The #ASCO25 meeting offered major updates. On Oncology Decoded, Benjamin Garmezy and @Mkbupathi rank top abstracts: ctDNA analysis from NIAGARA, disease-free survival with CAN-2409, safety data from Lu-PSMA-617, and more. ➡️mashupmd.com/expert-collect…

And listen to Oncology Decoded for more!

📌New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor A groundbreaking case study published in Oncogene (2025) demonstrates the first documented complete remission of a heavily pre-treated metastatic germ cell tumor using

iNKT Cells at the Interplay Between Innate and Adaptive Immune Responses - Hung Trinh Benjamin Garmezy Jennifer Buell Steven O'Day, MD oncodaily.com/insight/hung-t… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #iNKTCells #SalvageTherapy #GermCellTumor #TCells

Dr. Benjamin Garmezy et al. published in Oncogene: “MiNK Therapeutics’ allogeneic iNKT cell therapy, agenT-797, continues to gain recognition as a promising approach in solid tumors." oncodaily.com/insight/inkt-c…

Promising development as we continue to push cell therapy into solid tumors!

Excited to partner with World GU to help translate all of the new exciting data to help you in clinic tomorrow! Also register for World GU where our own Benjamin Garmezy and many others will be speaking on the latest updates in #guonc #prostatecancer #bladdercancer and #kidneycancer

Follow Oncology Decoded for more and excited to discuss the exciting treatments that are in development for #prostatecancer at World GU Conference!

🧬ctDNA is reshaping bladder cancer care. NIAGARA, TOMBOLA, and IMvigor trials show how it can guide treatment, predict recurrence, and personalize adjuvant therapy to support more precise decisions. Learn more from Benjamin Garmezy & @Mkbupathi: mashupmd.com/expert-collect…